Q-omics provides the consensus-scored MEN1 profile across patient tissues and cancer cell-line models. MEN1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MEN1 is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, MEN1 protein abundance shows 25,449 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, BLCA, and GBM as cancer lineages where MEN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEN1 survival associations across molecular data types. MEN1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEN1 RNA expression–survival associations across cancer types. High MEN1 expression shows unfavorable associations in KICH, ACC, LIHC, LGG, MESO and COAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MEN1 RNA expression.
This table summarizes MEN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MEN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEN1 shows higher tumor expression in BLCA, HNSC, KIRP, COAD, KIRC and STAD. The BLCA box plot shows higher MEN1 RNA expression in tumor versus normal tissue (log2 FC = +1.575, t-test p < 0.001).
This table shows molecular features associated with MEN1 in patient tissues and cancer cell lines. In patient samples, MEN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MEN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
